APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk.

BACKGROUND APOE is the most recognized genetic risk factor for sporadic late-onset Alzheimer disease (AD). The role of APOE genotype in Lewy body dementia (LBD) is still unknown as well as the relationship between APOE genotype and cholesterol levels. OBJECTIVE The objective of this study was to explore the association between APOE genotype and cholesterol levels in patients with LBD and those with AD. METHODS Eighty-two patients with LBD were consecutively enrolled as well as a comparable number of patients with AD and comparison group. Each subject underwent a clinical and neuropsychologic evaluation and APOE genotyping. RESULTS The distribution of APOE genotypes significantly differed between AD and LBD cases compared with the comparison group, with the APOE epsilon4+ (epsilon4+/epsilon4 + or epsilon4+/epsilon4-) genotype more frequent in patient subgroups. Different models have been fitted, and total APOE epsilon4-hypercholesterolemia complete interaction effect was claimed in predicting their relationship on disease outcome. Subjects with hypercholesterolemia and heterozygous for APOE epsilon4 allele had more than threefold risk to develop AD compared both with the comparison group and with those with LBD. The risk to develop AD in hypercholesterolemic and APOE epsilon4 homozygous subjects was 13-fold compared with the comparison group and those with LBD. Conversely, there was not evidence for APOE epsilon4-hypercholesterolemia complete interaction effect in LBD and in the comparison group. CONCLUSIONS This study highlighted that APOE is a risk factor not only for AD, but also for LBD, and that the APOE-cholesterol pathway differently affects AD and LBD. This approach may aid the search for the identification of an interactive effect of APOE genotype and modifiable risk factors, i.e., hypercholesterolemia, eventually resulting in individualized and effective cholesterol-lowering therapy in at-risk subjects.

[1]  J. Poirier,et al.  Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response , 2005, Experimental Neurology.

[2]  Judes Poirier,et al.  Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease , 2005, Neurobiology of Aging.

[3]  O. Lopez,et al.  Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease , 2005, Neurology.

[4]  B. Wolozin,et al.  Cholesterol, statins and dementia , 2004, Current opinion in lipidology.

[5]  David A. Bennett,et al.  Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer’s disease , 2004, Neurobiology of Aging.

[6]  Sophia Rabe-Hesketh,et al.  Generalized latent variable models: multilevel, longitudinal, and structural equation models , 2004 .

[7]  M. Luca,et al.  High cholesterol affects platelet APP processing in controls and in AD patients , 2003, Neurobiology of Aging.

[8]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[9]  M. Luca,et al.  Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease , 2003, Neuroscience Letters.

[10]  J. Poirier.  Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. , 2003, Trends in molecular medicine.

[11]  M. Michikawa.  The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. , 2003, Molecular neurobiology.

[12]  A. Singleton,et al.  Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies , 2002, Dementia and Geriatric Cognitive Disorders.

[13]  H. Kraemer,et al.  Mediators and moderators of treatment effects in randomized clinical trials. , 2002, Archives of general psychiatry.

[14]  B. Muthén,et al.  How to Use a Monte Carlo Study to Decide on Sample Size and Determine Power , 2002 .

[15]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[16]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[17]  David R. Anderson,et al.  Model Selection and Inference: A Practical Information-Theoretic Approach , 2001 .

[18]  H. Kraemer,et al.  How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. , 2001, The American journal of psychiatry.

[19]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[20]  A. Swann,et al.  Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies , 2000, Neurology.

[21]  P. Froom,et al.  Apolipoprotein E-ε4 genotype predicts a poor outcome in survivors of traumatic brain injury , 1999, Neurology.

[22]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[24]  J. Poirier,et al.  CHOLESTEROL TRANSPORT AND SYNTHESIS IN SPORADIC ALZHEIMER'S DISEASE , 2005 .

[25]  W. Kamphorst,et al.  Apolipoprotein E ε4 in an autopsy series of various dementing disorders , 2003 .

[26]  D. Rao,et al.  An epidemiologic approach to gene‐environment interaction , 1990, Genetic epidemiology.